Trials / Completed
CompletedNCT03934099
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group, Placebo and Active Comparator-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of LC350189 in Gout Patients With Hyperuricemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- LG Chem · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LC350189 formulated capsule | Xanthine Oxidase Inhibitor |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2019-12-02
- Primary completion
- 2021-05-03
- Completion
- 2021-05-17
- First posted
- 2019-05-01
- Last updated
- 2025-12-03
- Results posted
- 2025-12-03
Locations
34 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03934099. Inclusion in this directory is not an endorsement.